Symptom Suppression in Subjects with Perennial Allergic Rhinitis Treated with Mometasone Furoate Nasal Spray

Abstract

Background: Allergic rhinitis (AR) carries a high symptom burden and impact on quality of life. The ability of an AR treatment to achieve and sustain symptom suppression would be expected to enhance quality of life and improve long-term outcomes. Methods: In this ad hoc analysis of data from 4 phase 3 clinical trials of mometasone furoate nasal spray (MFNS), subjects with perennial AR recorded the severity of nasal symptoms twice daily for 12 weeks on a 4-point scale to determine the total nasal symptom score. Results: In the pooled sample of 1,149 subjects, 580 received MFNS 200 µg per day and 569 received placebo. Significantly more subjects receiving MFNS achieved symptom suppression versus those receiving placebo: 63.3% (n = 367) versus 51.0% (n = 290; p < 0.001). Median time to suppression was significantly shorter with MFNS versus placebo (29 vs. 59 days; p < 0.001). Total suppression was achieved in a significantly greater percentage of patients receiving MFNS versus placebo (36.0 vs. 25.5%; p < 0.001). Conclusions: A high level of symptom relief is attained faster and sustained longer with MFNS. This analysis validates the importance of treatment adherence to achieve optimal, sustained symptom relief.

Mometasone Furoate Nasal Spray plus Oxymetazoline Nasal Spray: Short-term Efficacy and Safety in Seasonal Allergic Rhinitis

“…1 Mometasone furoate nasal spray (MFNS) is an intranasal corticosteroid (INS) shown to be safe and efficacious for seasonal AR (SAR) and perennial AR (PAR). [2][3][4] Recent clinical trials established the ability of MFNS to significantly relieve SAR nasal symptoms, including congestion, for a full 24-hour dosing interval and to sustain relief over a 2-week treatment period. 2,5 Oxymetazoline (OXY) is an intranasal decongestant used to treat nasal congestion by activating ␣-adrenergic receptors, resulting in constriction of nasal blood vessels and, with rapid onset of action, improving airflow.…”

Safety, tolerability, pharmacokinetics, and pharmacodynamics of compound SFDAC by intranasal administration of multiple escalating dose in healthy male subjects

“…5 Complications can occur in allergic rhinitis and they can significantly impair quality of life. [9][10][11][12][13] Published data on safety and cost effectiveness of intranasal corticosteroids support the use of intranasal corticosteroids over oral antihistamines as first line treatment for allergic rhinitis. 8 Corticosteroids are widely used for suppression of inflammation in allergic rhinitis as well as in other chronic inflammatory diseases.…”

“…A survey results published in year 2011 reported that patients with allergic rhinitis were on about additional nine prescriptions than similar patients without allergic rhinitis, resulting in an incremental healthcare cost amounting to nearly 1,500 US $ per year . Corticosteroids are widely used for suppression of inflammation in allergic rhinitis as well as in other chronic inflammatory diseases . Published data on safety and cost effectiveness of intranasal corticosteroids support the use of intranasal corticosteroids over oral antihistamines as first line treatment for allergic rhinitis …”